Literature DB >> 31774912

A comprehensive evaluation of connectivity methods for L1000 data.

Kequan Lin1, Lu Li1, Yifei Dai2, Huili Wang2, Shuaishuai Teng2, Xilinqiqige Bao3, Zhi John Lu1,4,5, Dong Wang2,4,6,7.   

Abstract

The methodologies for evaluating similarities between gene expression profiles of different perturbagens are the key to understanding mechanisms of actions (MoAs) of unknown compounds and finding new indications for existing drugs. L1000-based next-generation Connectivity Map (CMap) data is more than a thousand-fold scale-up of the CMap pilot dataset. Although several systematic evaluations have been performed individually to assess the accuracy of the methodologies for the CMap pilot study, the performance of these methodologies needs to be re-evaluated for the L1000 data. Here, using the drug-drug similarities from the Drug Repurposing Hub database as a benchmark standard, we evaluated six popular published methods for the prediction performance of drug-drug relationships based on the partial area under the receiver operating characteristic (ROC) curve at false positive rates of 0.001, 0.005 and 0.01 (AUC0.001, AUC0.005 and AUC0.01). The similarity evaluating algorithm called ZhangScore was generally superior to other methods and exhibited the highest accuracy at the gene signature sizes ranging from 10 to 200. Further, we tested these methods with an experimentally derived gene signature related to estrogen in breast cancer cells, and the results confirmed that ZhangScore was more accurate than other methods. Moreover, based on scoring results of ZhangScore for the gene signature of TOP2A knockdown, in addition to well-known TOP2A inhibitors, we identified a number of potential inhibitors and at least two of them were the subject of previous investigation. Our studies provide potential guidelines for researchers to choose the suitable connectivity method. The six connectivity methods used in this report have been implemented in R package (https://github.com/Jasonlinchina/RCSM).
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  L1000; ZhangScore; connectivity map; connectivity methods; drug repurposing; partial area under the ROC

Year:  2020        PMID: 31774912     DOI: 10.1093/bib/bbz129

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  6 in total

1.  Reconciling multiple connectivity scores for drug repurposing.

Authors:  Kewalin Samart; Phoebe Tuyishime; Arjun Krishnan; Janani Ravi
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

2.  MNBDR: A Module Network Based Method for Drug Repositioning.

Authors:  He-Gang Chen; Xiong-Hui Zhou
Journal:  Genes (Basel)       Date:  2020-12-27       Impact factor: 4.096

3.  Drug repositioning by merging active subnetworks validated in cancer and COVID-19.

Authors:  Marta Lucchetta; Marco Pellegrini
Journal:  Sci Rep       Date:  2021-10-06       Impact factor: 4.379

4.  Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs.

Authors:  Pengchen Liang; Jin Li; Jianguo Chen; Junyan Lu; Zezhou Hao; Junfeng Shi; Qing Chang; Zeng Zeng
Journal:  Sci Rep       Date:  2022-05-03       Impact factor: 4.379

5.  Transcriptome‑based drug repositioning identifies TPCA‑1 as a potential selective inhibitor of esophagus squamous carcinoma cell viability.

Authors:  Zongyang Li; Linjun Zou; Zhi-Xiong Xiao; Jian Yang
Journal:  Int J Mol Med       Date:  2022-04-13       Impact factor: 4.101

Review 6.  Drug repositioning: A bibliometric analysis.

Authors:  Guojun Sun; Dashun Dong; Zuojun Dong; Qian Zhang; Hui Fang; Chaojun Wang; Shaoya Zhang; Shuaijun Wu; Yichen Dong; Yuehua Wan
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.